Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13272016 | 0.83 | TLR7 (0.64) | TLR7HTR2AHTR2BPDE4DLMNA | |
| Epetirimod SCHEMBL29350668 | 0.79 | TLR7 (0.70) | TLR7HTR2AHTR2BPDE4DLMNA | |
| Epetirimod SCHEMBL29454521 | 0.79 | TLR7 (0.70) | TLR7HTR2AHTR2BPDE4DLMNA | |
| Epetirimod SCHEMBL544542 | 0.79 | TLR7 (0.70) | TLR7HTR2AHTR2BPDE4DLMNA | |
| SCHEMBL3195223 | 0.77 | HTR2A (0.52) | TLR7HTR2AHTR2BPDE4DLMNA | |
| SCHEMBL544917 | 0.76 | CCR1 (0.39) | HTR2AHTR2BLMNAADRA1AHTR2C | |
| SCHEMBL13852043 | 0.74 | TLR7 (0.45) | TLR7HTR2AHTR2BPDE4DLMNA | |
| SCHEMBL5528022 | 0.74 | TLR7 (0.50) | TLR7HTR2AHTR2BPDE4DLMNA | |
| SCHEMBL5495408 | 0.73 | TLR7 (0.52) | TLR7HTR2AHTR2BPDE4DLMNA | |
| SCHEMBL2059214 | 0.73 | TLR7 (0.69) | TLR7HTR2AHTR2BPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149907-A1 | INFLUENZA VACCINES | Seqirus Inc. (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-118488850-A | Development method of peptide-based vaccine conjugated with 1V209 | 港大科桥有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-9078889-B2 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140187575-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8106202-B2 | Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor | FERRER INTERNACIONAL, S.A. (ES) | 2012-01-31 | — | — | US | disclosed |
| EP-1879893-B1 | METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR | FERRER INT (ES) | 2010-06-02 | — | — | EP | disclosed |
| EP-2061500-A2 | PHARMACEUTICAL AND SUNSCREEN COMPOSITIONS COMPRISING CASPASE-14 | VIB vzw (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090005566-A1 | Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor | FERRER INTERNACIONAL, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| WO-2008025830-A2 | PHARMACEUTICAL AND SUNSCREEN COMPOSITIONS COMPRISING CASPASE-14 | VIB VZW (BE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187575-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | TLR3, IFNAR1, LIG3 | TLR7 5/4885HTR2A 415/4885HTR2B 1221/4885 |
| US-20090005566-A1 | Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor | CYP4B1, QARS1, CYP4F11 | TLR7 1849/4885HTR2A 942/4885HTR2B 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.